Abstract:Optimal protein function often depends on co-operative interactions between amino acid residues distant in the protein primary sequence yet spatially near one another following protein folding. For example, antibody affinity is influenced by interactions of framework residues with complementarity-determining region (CDR) residues. However, despite the abundance of antibody structural information and computational tools the humanization of rodent antibodies for clinical use often results in a significant loss of affinity. To date, antibody engineering efforts have focused either on optimizing CDR residues involved in antigen binding or on optimizing antibody framework residues that serve critical roles in preserving the conformation of CDRs. In the present study a new approach which permits the rapid identification of co-operatively interacting framework and CDR residues was used to simultaneously humanize and optimize a murine antibody directed against CD40. Specifically, a combinatorial library that examined eight potentially important framework positions concomitantly with focused CDR libraries consisting of variants containing random single amino acid mutations in the third CDR of the heavy and light chains was expressed. Multiple anti-CD40 Fab variants containing as few as one murine framework residue and displaying up to approximately 500-fold higher affinity than the initial chimeric Fab were identified. The higher affinity humanized variants demonstrated a co-operative interaction between light chain framework residue Y49 and heavy chain CDR3 residue R/K101 (coupling energy, DeltaGI=0.9 kcal/mol). Screening of combinatorial framework-CDR libraries permits identification of monoclonal antibodies (mAb) with structures optimized for function, including instances in which the antigen induces conformational changes in the mAb. Moreover, the enhanced humanized variants contain fewer murine framework residues and could not be identified by sequential in vitro humanization and affinity muturation strategies. This approach to identifying co-operatively interacting residues is not restricted to antibody-antigen interactions and consequently, may be used broadly to gain insight into protein structure-function relationships, including proteins that serve as catalysts.

On the humanization of VHHs: Prospective case studies, experimental and computational characterization of structural determinants for functionality

Molecular basis for thermal stability and affinity in a VHH: contribution of the framework region and its influence in the conformation of the CDR3

Effect of Humanizing Mutations on the Stability of the Llama Single-Domain Variable Region

Antibody humanization—the Influence of the antibody framework on the CDR-H3 loop ensemble in solution

Development of novel humanized VHH synthetic libraries based on physicochemical analyses

Antibody light chain variable domains and their biophysically improved versions for human immunotherapy

Antibody humanization by redesign of complementarity-determining region residues proximate to the acceptor framework

Isolation and Characterization of Single-Domain Antibodies from Immune Phage Display Libraries

In silico design of stable single-domain antibodies with high affinity

Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.

AI/ML combined with next-generation sequencing of VHH immune repertoires enables the rapid identification of de novo humanized and sequence-optimized single domain antibodies: a prospective case study

Prospects for the computational humanization of antibodies and nanobodies

Promising Diagnostic and Therapeutic Approaches Based on VHHs for Cancer Management

A Simple Analysis of the Second (Extra) Disulfide Bridge of VHHs

Structure-based humanization of a therapeutic antibody for multiple myeloma

Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions

Global analysis of VHHs framework regions with a structural alphabet

Multispecific Antibody Development Platform Based on Human Heavy Chain Antibodies

Antibody Humanization By A Single Cycle Of Cdr-Grafting

Humanization Design of Antibody HAb18 Based on Variable Domain Resurfacing

Characterization of novel CD19-specific VHHs isolated from a camelid immune library by phage display